[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP055832A - Dihidrofenantridinosulfonamidas sustituidas - Google Patents

Dihidrofenantridinosulfonamidas sustituidas

Info

Publication number
ECSP055832A
ECSP055832A EC2005005832A ECSP055832A ECSP055832A EC SP055832 A ECSP055832 A EC SP055832A EC 2005005832 A EC2005005832 A EC 2005005832A EC SP055832 A ECSP055832 A EC SP055832A EC SP055832 A ECSP055832 A EC SP055832A
Authority
EC
Ecuador
Prior art keywords
dihydrophenantridinosulphonamids
substituted
arthritis
diseases
useful
Prior art date
Application number
EC2005005832A
Other languages
English (en)
Inventor
William Jay Moore
Mark Anthony Ashwell
Albert John Molinari
Amedeco Arturo Failli
Brian Hugh Ridgway
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32474616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055832(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055832A publication Critical patent/ECSP055832A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de las fórmulas (I) o (II) que tiene la estructura o una sal farmacéuticamente acceptable de él que son útiles para el tratamiento del componente inflamatorio de enfermedades y son particularmente útiles en el tratamiento de aterosclerosis, infarto de miocardio, insuficiencia cardíaca congestiva, enfermedad intestinal inflamatoria, artritis, diabetes tipo II, y enfermedades autoinmunes como esclerosis múltiple y artritis reumatoide.
EC2005005832A 2002-12-04 2005-06-02 Dihidrofenantridinosulfonamidas sustituidas ECSP055832A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43094902P 2002-12-04 2002-12-04
US10/718,461 US6894061B2 (en) 2002-12-04 2003-11-20 Substituted dihydrophenanthridinesulfonamides

Publications (1)

Publication Number Publication Date
ECSP055832A true ECSP055832A (es) 2005-08-11

Family

ID=32474616

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005832A ECSP055832A (es) 2002-12-04 2005-06-02 Dihidrofenantridinosulfonamidas sustituidas

Country Status (19)

Country Link
US (1) US6894061B2 (es)
EP (1) EP1567502B1 (es)
JP (1) JP4465280B2 (es)
KR (1) KR20050085321A (es)
AT (1) ATE370934T1 (es)
AU (1) AU2003298819A1 (es)
BR (1) BR0316196A (es)
CA (1) CA2508329A1 (es)
CR (1) CR7854A (es)
DE (1) DE60315874T2 (es)
DK (1) DK1567502T3 (es)
EC (1) ECSP055832A (es)
ES (1) ES2291739T3 (es)
MX (1) MXPA05006003A (es)
NO (1) NO20053204L (es)
NZ (1) NZ540440A (es)
RU (1) RU2005118070A (es)
TW (1) TW200510322A (es)
WO (1) WO2004050631A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119276A1 (en) * 2003-09-24 2005-06-02 Wyeth Methods of treating inflammatory bowel disease using NF-kB inhibitors
US20050113405A1 (en) * 2003-09-24 2005-05-26 Wyeth Methods of treating rheumatoid arthritis using NF-kB inhibitors
EP1652841A1 (en) * 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes
BRPI0512236A (pt) * 2004-06-18 2008-02-19 Wyeth Corp processos para a preparação de 6-alquil-5-arilsulfonil-diidrofenantridinas
US7304073B2 (en) * 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
KR20070051877A (ko) * 2004-09-02 2007-05-18 와이어쓰 사이토킨 조절제로서의 페난트리딘 카보닐 페놀
EP1856151A2 (en) 2005-01-19 2007-11-21 Wyeth Estrogen receptor structure
HU230518B1 (hu) * 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
US12084456B2 (en) 2018-12-05 2024-09-10 The Board Of Trustees Of The University Of Illinois Isocarbostyril alkaloids and functionalization thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135947A (en) 1965-04-20 1968-12-11 Aspro Nicholas Ltd Novel biologically active derivatives of phenanthridone
EP0509756A1 (en) 1991-04-16 1992-10-21 Merck & Co. Inc. 2-Phenanthridonyl carbapenems having cationizeable substituents
EP0509780A1 (en) 1991-04-16 1992-10-21 Merck & Co. Inc. 2-phenanthridonyl carbapenems
US5153185A (en) 1991-04-16 1992-10-06 Merck & Co., Inc. 2-phenanthridonyl carbapenems
US5726186A (en) 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
ES2189235T3 (es) 1997-07-25 2003-07-01 Altana Pharma Ag 6-fenilfenantridinas sustituidas.
IL144026A0 (en) 1999-01-15 2002-04-21 Byk Gulden Lomberg Chem Fab Phenylphenanthridine derivatives and pharmaceutical compostions containing the same
DE60033918D1 (de) 1999-01-15 2007-04-26 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
WO2002005616A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators

Also Published As

Publication number Publication date
DE60315874T2 (de) 2008-05-15
TW200510322A (en) 2005-03-16
DK1567502T3 (da) 2007-10-29
AU2003298819A1 (en) 2004-06-23
EP1567502B1 (en) 2007-08-22
US20040167155A1 (en) 2004-08-26
CR7854A (es) 2006-04-28
NZ540440A (en) 2006-11-30
NO20053204D0 (no) 2005-06-30
KR20050085321A (ko) 2005-08-29
BR0316196A (pt) 2005-09-27
CA2508329A1 (en) 2004-06-17
DE60315874D1 (de) 2007-10-04
JP2006510631A (ja) 2006-03-30
MXPA05006003A (es) 2005-08-18
WO2004050631A1 (en) 2004-06-17
ES2291739T3 (es) 2008-03-01
JP4465280B2 (ja) 2010-05-19
NO20053204L (no) 2005-09-05
RU2005118070A (ru) 2006-01-27
US6894061B2 (en) 2005-05-17
ATE370934T1 (de) 2007-09-15
EP1567502A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
MXPA05011581A (es) Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos.
CR7854A (es) Dihidrofenantridinosulfonamidas sustituidas
EA200500017A1 (ru) Новые соединения
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20083743L (no) Pyrimidinylsulfonamidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
DK1940826T3 (da) Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
MX2010003614A (es) Compuestos de diarilo oxadiazol.
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
ITMI20030709A1 (it) Miscele di stabilizzanti.
BR9811599A (pt) Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4
EA201070238A1 (ru) Соединения пиримидина
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
NO20043900L (no) Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner
EA200501274A1 (ru) Пиразолы и способы их получения и применения
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20000450L (no) Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
ATE240328T1 (de) Substituierte azaoxindolederivate
MX2010007026A (es) Derivados de triazoloxadiazoles.
DK1562954T3 (da) CCR1-antagonister til behandling af I.A. inflammatorisk demyelinisationssygdom
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
BRPI0415355A (pt) triarilimidazóis
PT1334094E (pt) Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.